Categoria: Abstract

Home / Abstract
Articolo

Treatment outcomes in patients (pts) with melanoma brain metastases (MBM) undergoing systemic therapy: A systematic literature review (SLR) and meta-analysis (MA) of real-world evidence (RWE)

Background Immunotherapy (IO) and targeted therapy (TT) have revolutionized the treatment of pts with MBM, but clinical data on their efficacy are scarce. This analysis summarizes available RWE on the systemic treatment outcomes for pts with MBM. Methods An SLR of RWE for any systemic treatment in pts with MBM was conducted by searching Embase®...

Articolo

Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage IIIB-D melanoma patients (pts) stratified according to the interferon-gamma signature (IFN-γ sign): The DONIMI study

Background Neoadjuvant (neoadj) IPI + NIVO induces high pathologic response rates (pRR 72-78%) in stage IIIB-D melanoma which is strongly associated with long-term relapse-free survival (RFS). Pts with a low baseline IFN-γ sign are less likely to respond. The class I histone deacetylase inhibitor domatinostat (DOM) increased intratumoral T cell infiltration and IFN-γ sign expression...

Articolo

CheckMate 204: 3-year outcomes of treatment with combination nivolumab (NIVO) plus ipilimumab (IPI) for patients (pts) with active melanoma brain metastases (MBM)

Background In CheckMate 204, asymptomatic pts (cohort A) with active, untreated MBM achieved high intracranial (IC) and extracranial (EC) response rates with NIVO + IPI; efficacy was lower in pts with symptomatic and/or steroid-requiring MBM (cohort B). Here, we report 3-y response and survival outcomes in both cohorts, along with first results of the blinded...

Articolo

MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL)

Background In the phase Ib part of MASTERKEY-265, T + P showed promising complete response rate (CRR) of 33% in 21 patients (pts) with advanced MEL. Here we report efficacy and safety from the phase III, randomized, double-blind MASTERKEY-265/KEYNOTE-034 study of T + P vs Pbo + P in pts with stage IIIB–IVM1c MEL (NCT02263508)....

Articolo

The effect of COVID-19 emergency in the management of melanoma in Italy

Abstract The COVID-19 pandemic has severely hampered the functioning of any health system, absorbing a considerable amount of resources and with the threat of widespread infection in the health services. The present survey has been carried out in Italy to evaluate if and how COVID-19 also affected skin melanoma management. We enrolled 13 Italian centres...

Articolo

Consensus Guidelines for the Management of Melanoma during the COVID-19 Pandemic: Surgery, Systemic Anti-cancer Therapy, Radiotherapy and Follow-up

Consensus Guidelines for the Management of Melanoma during the COVID-19 Pandemic: Surgery, Systemic Anti-cancer Therapy, Radiotherapy and Follow-up The current COVID-19 pandemic has major implications for the ability to deliver normal care for patients. Although Sir Simon Stevens, Chief Executive of NHS England, recommends ‘referrals, diagnostics and treatment to be brought back to pre-pandemic levels...

Articolo

The magnitude of COVID-19’s effect on the timely management of melanoma and nonmelanoma skin cancers

The magnitude of COVID-19’s effect on the timely management of melanoma and nonmelanoma skin cancers. To the Editor: The coronavirus disease 2019 (COVID-19) pandemic substantially reduced patient volumes or caused full closings of many US dermatology practices.1 , 2 Given reduced access to care and National Comprehensive Cancer Network guidelines to defer surgical management,3 concerns...

Articolo

Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study

Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study   Objectives To estimate the impact of the COVID-19 pandemic on cancer care services and overall (direct and indirect) excess deaths in people...

Articolo

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study   Background Data on patients with COVID-19 who have cancer are lacking. Here we characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify potential prognostic factors for mortality and severe illness. Methods In this cohort study, we collected...

Articolo

Mortality due to cancer treatment delay: systematic review and meta-analysis

Mortality due to cancer treatment delay: systematic review and meta-analysis. Abstract Objective To quantify the association of cancer treatment delay and mortality for each four week increase in delay to inform cancer treatment pathways. Design Systematic review and meta-analysis. Data sources Published studies in Medline from 1 January 2000 to 10 April 2020. Eligibility criteria...